Disappointing results from fingolimod trial in primary progressive MS
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
Last updated: 16th December 2014
Preliminary results from the Phase III INFORMS study of fingolimod in primary progressive MS have not shown a slowing down of MS worsening over the three-year study period.
INFORMS is a double-blind, randomized, multi-centre study, comparing the efficacy and safety of fingolimod (0.5 mg) versus placebo in people with primary progressive MS.
It is the largest clinical trial ever conducted in people with primary progressive MS, involving 970 people from 18 countries in Europe and the USA.
These results contrast with the consistently strong efficacy of fingolimod when used to treat relapsing MS.
These preliminary results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms.